Company Profile

PathAI

PathAI: Transforming Pathology with AI, Precision, and Innovation

Written By : Srinivas
Reviewed By : Sankha Ghosh

PathAI, an AI healthcare business located in the United States, is revolutionizing pathology with highly advanced machine learning technologies that improve diagnostic accuracy, shorten timelines for drug development, and enable precision medicine, while simultaneously changing the clinical workflows for digital pathology and elevating the standard of care globally.

Company Overview

PathAI is enhancing cancer diagnostics and therapeutics through disruptive artificial intelligence technologies. Its world-class platforms are creating seamless digital pathology workflows and enabling collaboration among pathologists and biopharma innovators that lead health advances. 

PathAI has raised over $255 million and is developing a CAP / CLIA laboratory in Memphis, TN to help spur a new era of precision medicine using technology and community discovery.

Legal NamePathAI, Inc.
HeadquartersBoston, Massachusetts, United States
Business ModelB2B
Founding Date2016
No. of EmployeesApprox 505 (As of 2025)

Products and Services

PathAI offers the following products and services: Translational Research, Clinical Development Services, Real-World Data, Companion Diagnostics, IHCExplore™, PathExplore™, LiverExplore™, IBDExplore™, AISight® Digital Pathology Platform, AI Product Solutions, Precision Pathology Network, BioPharma Services, AI Product Menu, and BioPharma Lab Services.

Core Leadership Team

Andy BeckChief Executive Officer, Co-founder
Brandon EldredgeChief Financial Officer
Liz StortiChief People Officer
Eric Walk, MD, FCAPChief Medical Officer
Nick BrownChief Growth Officer
Chris Kirby, JDGeneral Counsel

Revenue Streams

PathAI earns revenue through AI diagnostics, platform licensing, lab services, research collaborations, and strategic partnerships with leading biopharma companies.

PathAI

B2B

Client Segments: Healthcare Providers, Pathology Labs, Biopharma Companies, Research Institutions

Target Companies: Large Healthcare Systems, Pharmaceutical Firms, Diagnostic Labs, Clinical Research Organizations

Target Geography: Global, including North America, Europe, Asia-Pacific, Latin America, and the Middle East

Social Media Handle

Why Stablecoins and Tokenized Assets Attract Institutional Investors

Dogecoin Price Prediction: 300x Rally Could Push DOGE Above $20

BlockDAG Draws Heavy Attention As $0.00000044 Entry & $0.03 Buyback Outshine ADA And XLM!

Solana Forecast: Is SOL Heading Into the $40–$60 Support Zone?

Next Crypto to Explode in June 2026: BlockDAG, SUI, Cardano, Dogecoin, & Ethena Delivering Real-World Utility